Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

(2018) Michaela Tsai et al.   JAMA Oncology

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

(2017) Anne Kuijer et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of MammaPrint on Clinical Decision-Making in South African Patients with Early-Stage Breast Cancer

(2016) Heinrich Pohl et al.   Breast Journal

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene-Expression-Based Predictors for Breast Cancer

(2015) Arjun Gupta et al.   ANNALS OF SURGICAL ONCOLOGY

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups

(2015) Katharine Yao et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

(2014) Pat Whitworth et al.   ANNALS OF SURGICAL ONCOLOGY

European inter-institutional impact study of MammaPrint

(2014) P.G. Cusumano et al.   BREAST

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer

(2014) R Exner et al.   BRITISH JOURNAL OF CANCER

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy

(2014) Soley Bayraktar et al.   MEDICAL ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

(2013) Stefan Glück et al.   BREAST CANCER RESEARCH AND TREATMENT

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

(2013) C.A. Drukker et al.   INTERNATIONAL JOURNAL OF CANCER

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

(2011) Oscar Krijgsman et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

(2010) M. Ishitobi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age

(2009) S. Mook et al.   ANNALS OF ONCOLOGY

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

(2008) Stella Mook et al.   BREAST CANCER RESEARCH AND TREATMENT

Validation of 70-gene prognosis signature in node-negative breast cancer

(2008) J. M. Bueno-de-Mesquita et al.   BREAST CANCER RESEARCH AND TREATMENT

Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort

(2008) B. S. Wittner et al.   CLINICAL CANCER RESEARCH

Enabling personalized cancer medicine through analysis of gene-expression patterns

(2008) Laura J. van 't Veer et al.   NATURE